CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0553 (clinicaltrials.gov NCT No: NCT00427557)
Title:Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic
Hematopoietic Stem Cell Transplantation
Principal Investigator:Partow Kebriaei
Treatment Agent:Cord Blood Transplantation; Fludarabine; Melphalan; Rituximab
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if giving umbilical cord
blood along with standard stem cells after high-dose chemotherapy will improve
the response to a stem cell transplant. The safety of this treatment will also
be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma; Myeloma
Phase of Study:Phase II
Treatment Agents:Cord Blood Transplantation
Fludarabine
Melphalan
Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:100 days post transplant, and will include inpatient and out patient care
during this time period.
Supported By:N/A
Return Visit:Every 3 months during the first year as feasible.
Home Care:IV fluids, etc. as determined by patient's clinical status.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Partow Kebriaei
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-745-0663
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults